These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36908268)

  • 41. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review).
    Choucair K; Radford M; Bansal A; Park R; Saeed A
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34396449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metronomic chemotherapy as a potential partner of immune checkpoint inhibitors for metastatic colorectal cancer treatment.
    Hong JH; Woo IS
    Cancer Lett; 2023 Jul; 565():216236. PubMed ID: 37209943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
    Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
    Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
    Front Immunol; 2022; 13():974793. PubMed ID: 36700211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
    Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
    Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis.
    Toh JWT; Phan K; Reza F; Chapuis P; Spring KJ
    Int J Colorectal Dis; 2021 Aug; 36(8):1573-1596. PubMed ID: 33604737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MSI colorectal cancer, all you need to know.
    Flecchia C; Zaanan A; Lahlou W; Basile D; Broudin C; Gallois C; Pilla L; Karoui M; Manceau G; Taieb J
    Clin Res Hepatol Gastroenterol; 2022 Nov; 46(9):101983. PubMed ID: 35732266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Profiling Provides Clinical Insights Into Targeted and Immunotherapies as Well as Colorectal Cancer Prognosis.
    Guo L; Wang Y; Yang W; Wang C; Guo T; Yang J; Shao Z; Cai G; Cai S; Zhang L; Hu X; Xu Y
    Gastroenterology; 2023 Aug; 165(2):414-428.e7. PubMed ID: 37146911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Facts and Hopes in Colorectal Cancer Immunotherapy.
    Foote MB; Argilés G; Rousseau B; Segal NH
    Clin Cancer Res; 2023 Oct; 29(20):4032-4039. PubMed ID: 37326624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An update on the use of immunotherapy in patients with colorectal cancer.
    Nguyen M; Tipping Smith S; Lam M; Liow E; Davies A; Prenen H; Segelov E
    Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):291-304. PubMed ID: 33138649
    [No Abstract]   [Full Text] [Related]  

  • 55. Current Microsatellite Instability Testing in Management of Colorectal Cancer.
    Sun BL
    Clin Colorectal Cancer; 2021 Mar; 20(1):e12-e20. PubMed ID: 32888812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma.
    San-Román-Gil M; Torres-Jiménez J; Pozas J; Esteban-Villarrubia J; Albarrán-Fernández V; Álvarez-Ballesteros P; Chamorro-Pérez J; Rosero-Rodríguez D; Orejana-Martín I; Martínez-Delfrade Í; Reguera-Puertas P; Fuentes-Mateos R; Ferreiro-Monteagudo R
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
    BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.
    Cohen R; Pellat A; Boussion H; Svrcek M; Lopez-Trabada D; Trouilloud I; Afchain P; André T
    Bull Cancer; 2019 Feb; 106(2):137-142. PubMed ID: 30327191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of immunotherapy in mismatch repair-deficient advanced colorectal cancer in routine clinical practice. An AGEO study.
    Alouani E; Mercier M; Flecchia C; Auclin E; Hollebecque A; Mazard T; Turpin A; Pernot S; Cohen R; Dutherage M; Kim S; Sclafani F; Ben-Abdelghani M; Herve C; Aparicio T; De La Fouchardière C; Perkins G; Hautefeuille V; Jaffrelot M; Gallois C; Bongard V; Tougeron D; Taïeb J; Guimbaud R
    ESMO Open; 2023 Jun; 8(3):101574. PubMed ID: 37244250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.